🔎 Trials Near Me

Akèy › Leksemi mieloïd egi › Iowa

Etid klinik pou Leksemi mieloïd egi nan Iowa

17 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan Iowa.

Vil nan Iowa

Tèks ofisyèl etid la (Anglè)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mary Greeley Medical Center, Ames
  • McFarland Clinic - Ames, Ames
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • ak 12 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive
  • Iowa Methodist Medical Center, Des Moines
  • ak 7 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Blank Children's Hospital, Des Moines
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Ap rekriteFaz 3
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • University of Iowa Hospital, Iowa City
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Blank Children's Hospital, Des Moines
Ap rekriteFaz 3
Laj 1 a 25 · Tout sèks · Mizajou Sep 4, 2026 · NCT07022678

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

  • University of Iowa Hospital and Clinics, Iowa City
Ap rekriteEtid obsèvasyon
Laj 0 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07154823

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

  • University of Iowa Health Care, Iowa City
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 31, 2026 · NCT07177079

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Blank Children's Hospital, Des Moines
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • University of Iowa Stead Family Children's Hospital, Iowa City
Ap rekriteFaz 3
29 Days – 21 Years · Tout sèks · Mizajou Aug 24, 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Iowa, Iowa City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • University of Iowa Hospitals & Clinics, Iowa City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • University of Iowa Hospitals and Clinics, Iowa City
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 17, 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Iowa, Iowa City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • University of Iowa Hospitals & Clinics, Iowa City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.